Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

BACKGROUND: Rituximab (R) is a chimeric human-murine anti-CD20 monoclonal antibody used to treat B-cell lymphomas. Despite R remarkable activity against malignant cells, there are concerns that R may facilitate the occurrence of infections. This study is aimed to define risk factors for infections,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanini, Simone, Molloy, Aoife C, Prentice, Archibald G, Ippolito, Giuseppe, Kibbler, Christopher C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716624/
https://www.ncbi.nlm.nih.gov/pubmed/23849292
http://dx.doi.org/10.1186/1471-2334-13-317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716624/
https://www.ncbi.nlm.nih.gov/pubmed/23849292
http://dx.doi.org/10.1186/1471-2334-13-317

Ejemplares similares